MoonLake Immunotherapeutics (MLTX) News Today $39.67 -0.91 (-2.24%) Closing price 04:00 PM EasternExtended Trading$39.62 -0.05 (-0.13%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 2.9% - Still a Buy?MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 2.9% Higher - Still a Buy?March 19, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Royal Bank of CanadaRoyal Bank of Canada initiated coverage on MoonLake Immunotherapeutics in a report on Tuesday. They set an "outperform" rating and a $67.00 price objective on the stock.March 19, 2025 | marketbeat.comRBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform RecommendationMarch 18, 2025 | msn.comMoonLake Immunotherapeutics initiated with an Outperform at RBC CapitalMarch 18, 2025 | markets.businessinsider.comRBC Capital Initiates a Buy Rating on MoonLake Immunotherapeutics (MLTX)March 18, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics Advances Clinical Trials in 2024March 15, 2025 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. lowered its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 18.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 178,501 shares of the comMarch 14, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Hits New 52-Week Low - What's Next?MoonLake Immunotherapeutics (NASDAQ:MLTX) Reaches New 1-Year Low - Time to Sell?March 11, 2025 | marketbeat.comCandriam S.C.A. Sells 11,524 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Candriam S.C.A. lessened its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 227,476 shares of the company's stock after selling 11,524 sharesMarch 8, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Buy" by BrokeragesMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has received an average rating of "Buy" from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation anMarch 3, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for MLTX Q1 Earnings?MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Research analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst R. Selvaraju now forecasts that the companyMarch 3, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for MLTX Q1 Earnings?MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Leerink Partnrs issued their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a report released on Thursday, February 27th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($0.82)March 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Decreased by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd cut its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 54.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,229 shares of the company'sMarch 2, 2025 | marketbeat.comBrokers Offer Predictions for MLTX Q2 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for MoonLake Immunotherapeutics in a research report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith expects that the company will post earniMarch 1, 2025 | marketbeat.comWedbush Has Negative Forecast for MLTX Q1 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at Wedbush lowered their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research report issued to clients and investors on Wednesday, February 26th. Wedbush analyst Y. Zhong now anticipMarch 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Cut to $73.00 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group reduced their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a research report on Thursday.February 28, 2025 | marketbeat.comMoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday.February 28, 2025 | marketbeat.comNeedham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00Needham & Company LLC increased their target price on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a "buy" rating in a report on Thursday.February 28, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Announces Quarterly Earnings ResultsMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.09).February 27, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on ThursdayMoonLake Immunotherapeutics (NASDAQ:MLTX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comMoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c)February 26, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics Reports Q4 EPS of -$0. ...February 26, 2025 | gurufocus.comMoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateFebruary 26, 2025 | investing.comMoonLake Immunotherapeutics Advances Clinical Trials with Promising Financial OutlookFebruary 26, 2025 | gurufocus.comMoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateFebruary 26, 2025 | globenewswire.comIs MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?February 25, 2025 | msn.comMoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to AnalystsFebruary 23, 2025 | insidermonkey.comMoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20, 2025 | insidermonkey.comMoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20, 2025 | msn.comRice Hall James & Associates LLC Has $6.02 Million Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Rice Hall James & Associates LLC boosted its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 47.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,133 shares of the company's stock after buying an additional 3February 18, 2025 | marketbeat.comCongress Asset Management Co. Buys 6,352 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Congress Asset Management Co. grew its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 72,993 shares of the company's stock after acquiring anFebruary 18, 2025 | marketbeat.comFMR LLC's Strategic Acquisition of MoonLake Immunotherapeutics SharesFebruary 12, 2025 | gurufocus.comWe're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash WiselyFebruary 11, 2025 | finance.yahoo.comFY2025 Earnings Forecast for MLTX Issued By Leerink PartnrsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the compFebruary 10, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for MLTX FY2029 Earnings?MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities researchers at Leerink Partnrs issued their FY2029 earnings estimates for shares of MoonLake Immunotherapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the companFebruary 7, 2025 | marketbeat.comJPMorgan Chase & Co. Reduces Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)JPMorgan Chase & Co. trimmed its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 93.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,236 shares of the company's stock after selling 16,472 shares during the period. JPMorganFebruary 4, 2025 | marketbeat.comCantor Fitzgerald Estimates MLTX FY2025 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal forecastsJanuary 23, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6.3% - Here's What HappenedMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6.3% - Here's WhyJanuary 21, 2025 | marketbeat.comGoldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?January 19, 2025 | msn.comMoonLake Immunotherapeutics upgraded to Buy from Neutral at Goldman SachsJanuary 18, 2025 | markets.businessinsider.comPositive Outlook for MoonLake Immunotherapeutics: Buy Rating Driven by Promising Trial Results and Strategic ConsistencyJanuary 18, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced UponJanuary 17, 2025 | seekingalpha.comGoldman Sachs Upgrades MoonLake Immunotherapeutics (MLTX)January 17, 2025 | msn.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's WhyMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Still a Buy?January 17, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded at The Goldman Sachs GroupThe Goldman Sachs Group upgraded MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $62.00 to $82.00 in a research report on Friday.January 17, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average rating of "Moderate Buy" by the eight ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has gJanuary 12, 2025 | marketbeat.comMoonLake Immunotherapeutics: Strategic Expansion in Clinical Trials Positions Sonelokimab for Market GrowthJanuary 11, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics: Promising Prospects and Market Expansion with SonelokimabJanuary 10, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Friday.January 10, 2025 | marketbeat.comMoonLake Immunotherapeutics Poised for Transformational Growth: Buy Rating Affirmed on Strategic Clinical Expansion and Strong Financial PositionJanuary 9, 2025 | markets.businessinsider.com Remove Ads Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Media Mentions By Week MLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.290.68▲Average Medical News Sentiment MLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼43▲MLTX Articles Average Week Remove Ads Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SRPT News Today PCVX News Today QGEN News Today ROIV News Today RVMD News Today LNTH News Today LEGN News Today TGTX News Today BBIO News Today AXSM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLTX Stock Free MLTX Stock Alerts